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Abstract
Background: Recent data show differences in intraoperative neuromonitoring (IOM) in relation to the operated
brain lesion. Due to the recently shown infiltrative nature of cerebral metastases, this work investigates the
differences of IOM for cerebral metastases and glioma resection concerning sensitivity, specificity, and predictive
values when aiming on preservation of motor function.
Methods: Between 2006 and 2011 we resected 171 eloquently located tumors (56 metastases, 115 gliomas)
associated with the rolandic cortex or the pyramidal tract using IOM via direct cortical motor evoked potentials
(MEPs). Postoperatively, MEP data were re-analyzed with respect to surgery-related paresis, residual tumor, and
postoperative MRI with two different thresholds for MEP decline (50 and 80 % below baseline).
Results: MEP monitoring was successful in 158 cases (92.4 %). MEPs were stable in 54.7 % of all metastases cases
and in 65.2 % of all glioma cases (p < 0.0001). After metastases resection, 21.4 % of patients improved and 21.9 %
deteriorated in motor function. Glioma patients improved in only 5.4 % and worsened in 31.3 % of cases (p < 0.05).
Resection was stopped due to MEP decline in 8.0 % (metastases) and 34.8 % of cases (gliomas) (p < 0.0002).
Conclusion: There is significant difference between glioma and metastases resection. Post-hoc, metastases show
more stable MEPs but a surprisingly high rate of surgery-related paresis and therefore a higher rate of false
negative IOM.
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Background
For resection of gliomas within or adjacent to the motor
system intraoperative neuromonitoring (IOM) is now
widely used by many neurosurgeons [1–6]. Although
surgery is currently limited to a subgroup of patients
harboring brain metastases (BM), especially those symp-
tomatic with a focal deficit are still considered for surgi-
cal resection in order to achieve early recovery from
neurological deficits [7, 8]. Therefore, particularly metas-
tases within or adjacent to the rolandic cortex or corti-
cospinal tract (CST) are potentially treated by surgical
resection. As current reports have shown the infiltrative
nature of cerebral metastases, IOM of the motor systems
might be helpful to reduce surgery-related motor deficits
also in BM patiens and its use therefore increased re-
cently [3, 9–12].
Studies on IOM by motor evoked potentials (MEP) for
the resection of gliomas within the rolandic region or
CST used various warning criteria with various predict-
ive values even within a considerably homogeneous en-
tity like gliomas [13–17].
The present study, therefore provides data on IOM of
a large cohort of motor eloquently located tumors, but
also provides a profound analysis of IOM data, which
elucidates potential differences of IOM for surgery of
supratentorial metastases compared to gliomas as also
published earlier by our group. We especially focused on
sensitivity, specificity, and predictive values of different
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warning criteria for each tumor type. Awareness has to
be raised among neurosurgeons for these differences
when performing surgery in motor eloquent cortex or
fiber tracts for these tumor entities.
Methods
Patients
Between 2006 and 2011 171 consecutive patients with
motor eloquently located supratentorial tumors under-
went craniotomy in our department. All of our patients
were operated by one of 5 experienced neurosurgeons.
There were 56 brain metastases and 115 gliomas in or
adjacent to the rolandic cortex or the CST. All cases
were performed by monopolar direct cortical stimulation
for monitoring of MEPs. Topographic association be-
tween tumor and CST or rolandic cortex and therefore
indication for IOM was preoperatively assessed by mag-
netic resonance imaging (MRI). Moreover, prior to sur-
gery, each case was discussed on a case-by-case basis by
an interdisciplinary tumor board. Eligibility for surgery
was consented by all participating disciplines (neurosur-
gery, neurooncology, radiation oncology, medical oncol-
ogy) according to the present guidelines and recent
scientific evidence [19–23]. Concerning brain metasta-
ses, surgical resection was frequently recommended for
patients presenting with disabling motor weakness or le-
sions resistant to chemo- or radiotherapy. The enrolled
patient cohort is outlined in Table 1.
Ethical standard
The study is in accordance with ethical standards of the
Declaration of Helsinki and was approved by the local
institutional review board (IRB) of the Technical Univer-
sity Munich. The need for consent was waived by the
IRB (registration number: 2826/10).
Standardized patient evaluation
Preoperatively, 170 out of 171 patients underwent MRI
for tumor diagnosis, localization, and acquisition of a
navigational dataset for intraoperative neuronavigation
(BrainLAB Vector Vision 2®, BrainLAB Vector Vision Sky,
and BrainLAB Curve®, Feldkirchen, Germany) (Figure 1).
All patients were evaluated for muscle strength, coordin-
ation, sensory function, and cranial nerve function accord-
ing to a standardized protocol as described earlier [18].
Every patient received steroids preoperatively as part of
our clinical standards. Muscle strength was graded
according to the British Medical Research Council
Scale (BMRC).
Directly after anesthesia all patients were examined
routinely and further assessments were performed from
the first postoperative day until discharge. During
follow-up, first at 6–8 weeks after surgery, and on a
regular basis every 3–12 months this standardized
Table 1 Enrolled patients
Metastases Gliomas
Sex male 32 (61.0 %) 62 (59.1 %)
female 21 (39.0 %) 43 (40.9 %)






lung cancer 17 (30.0 %)
breast cancer 12 (21.0 %)
melanoma 5 (9.0 %),
colon 4 (7.0 %)
renal cancer 4 (7.0 %)
others 14 (26.0 %)
WHO I - 3 (2.7 %)
WHOII - 17 (15.2 %)
WHO III - 22 (19.6 %)
WHO IV - 70 (62.5 %)
Number 1 32 (57.0 %) 103 (100 %)
2 10 (18.0 %)
3 6 (11.0 %)
>3 8 (14.0 %)
location of tumor frontodorsal/SMA 27.0 % 32.0 %
precentral gyrus 37.0 % 16.0 %
postcentral gyrus 14.0 % 18.0 %
CST 22.0 % 34.0 %
preoperative status paresis 32 (57.0 %) 35 (31.3 %)
seizures 17 (30.0 %) 24 (21.4 %)
dizziness 5 (9.0 %) -
incidental 2 (4 %) -
hemihypesthesia - 19 (17.0 %)
MEP changes Intraoperative stable
posthoc analysis >50 %
amplitude loss
29 (54.7 %) 73 (65.2 %)
none (stable) 32 (60.0 %) 85 (80.1 %)
reversible 7 (13.0 %) 9 (8.6 %)
irreversible 14 (27.0 %) 11 (10.3 %)
>80 % amplitude loss
none (stable) 30 (56.6 %) 24 (22.9 %)
reversible 20 (37.7 %) 70 (66.7)
irreversible 3 (5.7 %) 11 (10.3 %)
surgery-related
deficits
temporary 5 (9.4 %) 19 (18.1 %)
permanent 7 (12.5 %) 14 (12.5 %)
Follow-up (months) Mean ± SD 2.9 ± 4.5 9.7 ± 10.5
Median 0.7 months 6.1
Min 0.1 0.5
Max 20.1 40.6
Overview of all enrolled patients including primary tumor, MEP changes
intraoperatively, and surgery-related deficits
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protocol was conducted again. On basis of these data,
temporary and permanent new surgery-related motor
deficits were defined. A new permanent deficit was de-
fined as a new or aggravated paresis due to resection
that did not resolve to the preoperative status during
follow-up (<6-8 weeks after surgery). A temporary deficit
was defined as a new or aggravated postoperative par-
esis, which disappeared at least during the regular 8-
week follow-up. Concerning postoperative imaging, all
patients who presented with a new paresis immediately
after surgery underwent a postoperative CT scan to exclude
to secondary hemorrhage or ischemia. These events were
regarded as secondary events, which could not be detected
by IOM and therefore were excluded from subset analysis.
Additionally, an MRI scan was performed within 48 h after
surgery to assess the extent of tumor resection, potential
diffusion impairment, increasing edema, or hemorrhage.
These data were also reviewed during this study in order to
find causes for potentially new postoperative deficits. Dur-
ing follow-up, MRI scans were also performed on a regular
basis every 3–12 months depending on tumor entity and
current adjuvant therapy. Follow-up MRI scans were
reviewed for recurrent metastases and gliomas since
the neurological status for this study was only consid-
ered during progression-free follow-up.
Intraoperative monitoring and resection procedure
All patients underwent surgical resection under total intra-
venous anesthesia (TIVA) by continuously administration
of propofol and remifentanyl and volatile anesthetics were
strictly avoided due to their interference with evoked po-
tentials [16, 24, 25]. Neuromuscular blocking by rocuro-
nium was used for intubation only and was avoided during
surgery for the same reason. Continuous IOM by MEP
monitoring was performed by a strip electrode with four
to eight contacts (ADTech® strip electrode, AD Technic,
City, WI, USA or Inomed Medizintechnik, Emmendingen,
Germany), which was positioned onto the hand knob of
the precentral gyrus. Subcortical stimulation was only used
if needed in this particular surgical step. Somatosensory
evoked potential phase reversal or preoperative mapping
by navigated transcranial magnetic stimulation confirmed
the location of the pre- and postcentral gyrus and the cen-
tral sulcus [26–28]. For detection of compound muscle ac-
tion potentials (CMAPs), 27-gauge disposable subdermal
needle electrodes (AD-Tech needle electrode, AD-Tech, or
Inomed needle electrode, Inomed Medizintechnik) were
placed in a bipolar way with a distance of approximately
10 mm over relevant muscles of the contralateral side of
the tumor in a standardized way: the thenar (abductor pol-
licis brevis), hypothenar (adductor digiti minimi), flexor
carpi radialis, and brachial biceps for the upper extremity
and the anterior tibial muscle for the lower extremity. Pro-
cessing of the obtained data was achieved by the Axon
EpocheXPe neuromonitoring system (Axon Systems,
Hauppauge, New York) or the Inomed ISIS IOM system
(Inomed Medizintechnik).
For stimulation, square-wave pulses with a duration of
200 to 300 microseconds, a frequency of 350 Hz, and a
train of 5 pulses were applied. Stimulation intensity
began with 6 mA and was increased continuously in
steps of 1 mA until we were able to record a CMAP or
until an upper limit of 30 mA was applied without elicit-
ing a CMAP.
Every 2 to 60 s, sequential MEP monitoring was then
performed by anodal direct cortical or subcortical stimula-
tion of the rolandic cortex or CST until end of resection
and before dural closure extensively described in earlier
reports [2, 17, 29]. MEPs were continuously recorded and
analyzed in real-time and monitored for amplitude and la-
tency at least every 60 s by a technologist trained as a
neurophysiologist or a neurosurgeon with certification in
Fig. 1 Illustrative MRIs. Two T1 weighted contrast-enhanced MR images showing motor eloquently located glioma within the central sulcus (left)
and metastasis in the precentral gyrus (right) as enrolled in this analysis
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IOM. Depending on the status of the resection, intervals
were shortened to 2 s to assure maximum safety during
critical steps of resection. The MEP amplitude was evalu-
ated by measuring peak-to-peak differences, whereas la-
tency was defined as the span between the sequence start
of the stimulation and the first assessable amplitude as
also reported by other groups [17, 23, 29, 30]. During sur-
gery, an amplitude decrease of 50 % or more of the base-
line was considered a considerable decline and was
immediately reported to the surgeon if not caused by
technical issues. However, final consideration of the IOM
data was left to the operating surgeon. He or she then re-
versed the supposed underlying surgical step, removed
spatulas, or irrigated the exposed cortex and vasculature
with warm Ringer’s solution. Moreover, when the resec-
tion was close to major blood vessels irrigation with nimo-
dipine was performed to potentially reverse or avoid
vasospasm. As soon as MEP amplitudes stabilized or re-
covered, tumor resection continued. Moreover, when
MEP failed to recover, resection was stopped at this part
of the resection cavity.
Post-hoc analysis of IOM data
Because a 50 % decline in amplitude was intraoperatively
considered significant, all further data concerning surgi-
cal steps are related to this rule. A latency increase with-
out simultaneous deterioration of amplitude was never
seen in this series, so latency was excluded as a warning
criteria. As all IOM data were routinely recorded and
stored after every surgery, we were able to review these
data post-hoc to determine the predictive value of differ-
ent threshold values of substantial amplitude decline with
respect to the patient’s postoperative status. Based on
previous data of our and other groups, an amplitude
decline of >50 and >80 % of baseline were therefore
evaluated [2, 5, 6, 14, 31]. With regard to intraoperative
data, incomplete reduction of compound muscle action
potential (CMAP) was valued as deterioration rather
than loss.
Statistical analysis
For testing the distribution of several attributes, a Chi-
square or Fisher Exact test was performed. Differences
between 2 groups were tested using the Mann–Whitney-
Wilcoxon test for multiple comparisons on ranks for inde-
pendent samples. Differences between groups were tested
by the Kruskall-Wallis test for nonparametric one-way
analysis of variance (ANOVA) followed by Dunn’s test as
the post hoc test. All results are presented as mean ±
standard deviation (SD). Median and range were also cal-
culated (GraphPad Prism 5.0c, La Jolla, CA, USA); p < 0.05
was considered significant.
Results
MEP monitoring was successful in 53 metastases
(92.9 %) and 105 gliomas (90.5 %). Table 1 presents spe-
cific details of enrolled patients such as sex, age, type of
primary cancer in metastases and number, location of
tumor, preoperative status, MEP changes, and surgery-
related deficits.
Postoperative results
In general, both patients of each group suffered almost
equally from a new permanent deficit due to surgery
(BM 9.4 % vs. 12.5 % glioma), while 21 % of the BM
group and 5.4 % of the glioma group showed improved
strength due to surgery, 16.4 % of the BM group and
13.4 % of the glioma group worsened postoperatively
(Fig. 2). Gross total resection (GTR) was intraoperatively
estimated in the glioma group in 70.6 % (n = 77) and in
the BM group in 92.5 % (n = 49) (p = 0.0013). Subtotal
resection (STR) detected by postoperative MRI study
was seen in 41.4 % of glioma patients (n = 46) and in
28.0 % of BM patients (n = 14) (p = 0.115). So we had to
face an unexpected residual (UR) in 21.0 % of BM cases
and in 12.0 % of glioma cases without showing statisti-
cally significant difference.
Correlation of tumor type and location to postoperative
deficit
WHO grade of the tumor did not play a significant role
for postoperative temporary or permanent impairment
of motor function (p = 0.6013), but a trend towards a
correlation of high grade tumors and degree of postoper-
ative deficit is shown. None of the patients harboring
WHO grade I tumors developed a new surgery-related
deficits. In the WHO grade II group all new deficits
were only temporary in 17.6 % of cases (n = 3). Regard-
ing high-grade glioma (WHO grade III and IV)
Fig. 2 Differences in motor status. Differences in motor status during
long-term follow-up between patients harboring metastases and
gliomas (p< 0.05)
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temporary deficits occurred in 22.7 (n = 5) and 18.6 %
(n = 13) of cases. Permanent deficits were seen in 13.6
(n = 3) and 14.3 % (n = 10) in these patients. Tumor lo-
cation and postoperative temporary and permanent im-
pairment of motor function showed statistically
significant differences only in the BM group (BM: p =
0.0209 vs. gliomas: p = 0.6013).
Intraoperative neuromonitoring
In 13 (3 BM and 10 gliomas) out of all 171 enrolled pa-
tients IOM was not possible. In a small number of cases
displacement of the strip electrode occurred during re-
section with temporary stop of IOM or minor venous
bleeding after removal of the strip electrode. There were
no monitoring-related complications in all but one case,
in which DCS caused an intraoperative focal seizure. Table 1
presents the intraoperatively judged stability of MEPs as
graded by the neurophysiologist. The neurophysiologist
gave constant information about MEP amplitudes and re-
ported an amplitude reduction of more than 50 % of base-
line to the surgeon. In all of these cases the surgeon
temporarily stopped tumor resection, irrigated the surgical
field, and/or released retractors. Results of IOM are given
in the following and Table 2.
Post-hoc analysis: MEP reduction >50 %
The post-hoc analysis of MEP recordings revealed stable
MEP-amplitudes in only 7 BM cases (13.0 %) with un-
changed neurological status in all of these cases.
We found stable MEP amplitudes in 9 glioma patients.
In 5 cases (55.5 %) there was no change of postoperative
status but in 4 other cases (44.5 %) we discovered new
postoperative deficits, which not resolved in one case
(11.1 %) (Fig. 3a).
Reversible decline >50 %
Out of 32 cases 25 BM patients (78.1 %) showed no new
deficit. A new temporary motor deficit was found in
17.0 % (5 pts), and in 7.0 % (2 pts) motor function
permanently deteriorated compared to the preoperative
status. Both patients suffered from metastases within the
precentral gyrus. In one case postoperative MRI revealed
secondary postoperative hemorrhage and in the other
patient an ischemic lesion was shown. Both presented
with delayed paresis, which cannot always be detected by
IOM. Thus, these events were considered to be secondary.
Fig. 3c presents the data without those cases of secondary
events. MEP amplitude reduction caused stop of resection
in 6.0 % of these cases (2 patients). Postoperative MRI re-
vealed residual tumor in one of these 2 cases.
In 85 glioma patients with reversible MEP decline 66
(77.6 %) remained their neurological status, while 19 pa-
tients developed transient (14 patients; 16.5 %) or per-
manent (5 patients; 5.9 %) new pareses. In these 5
patients suffering from permanent deficits MRI showed
4 secondary hemorrhages and one ischemia, which have
to be seen as a secondary events and therefore not ne-
cessarily detectable by IOM (Fig. 3b).
Irreversible MEP decline >50 %
MEP recordings in BM cases showed an irreversible de-
cline in 27.0 % (14 patients) of cases. No postoperative
deterioration was observed in 11 patients, which represents
false positive IOM. When investigating the time of contin-
ued IOM after amplitude decline, we found a range of IOM
2–27 min (median 4.7 min, mean 7.3 min) after >50 % de-
cline. Maybe this period of IOM after MEP decline was too
short to detect any MEP recovery. All but one patient har-
boring eloquently located gliomas and experiencing an in-
traoperative MEP decline of >50 % (n = 11) presented a
new postoperative motor deficit. We found 2 temporary
and 8 permanent pareses and had to deal with one false
positive case (Table 2).
Post-hoc analysis: Intraoperative MEP reduction >80 %
Regarding 80 % decline of initial MEP amplitude as consid-
erable deterioration, we found stable results for IOM in
56.0 % (30 patients) of BM cases and in 22.9 % (24 patients)
Table 2 False positive and negative results
Gliomas Metastases
MEP decline new deficits temp perm new deficits temp perm
MEP decline >50 % stable 4/9 (44.4 %) 3 (33.3 %) 1 (11.1 %/1B) 0/7 (0.0 %) 0 0
reversible 19/85 (22.4 %) 14 (16.5 %) 5 (5.9 %/4B, 1I) 7/32 (21.8 %) 5 (17.2 %) 2 (6.9 %/1B,1 I)
irreversible 10/11 2 (18.2 %) 8 (72.7 %) 3/14 0 3 (21.4 %)
false positive 1 - - 11 - -
MEP decline >80 % stable 5/24 (20.9 %) 4 (16.7 %) 1(4.1 %/1I) 4/30 (14.0 %) 2 (6.7 %) 2 (6.7 %/1B,1 I)
reversible 18/70 (25.7 %) 13 (18.6 %) 5 (7.1 %/4B, 1I) 4/20 (20.0 %) 3 (15 %) 1 (5.0 %/1B)
irreversible 10/11 (90.9 %) 2 (18.2 %) 8 (72.7 %) 3/3 (100 %) - 2 (66.7 %/1U)
false positive 1 - - 1 - -
B = Bleeding, I = Ischemia, E = Edema, U = Unknown; Showing all cases of false positive and negative results considering postoperative outcome in relation to
postoperative MRI scan
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Fig. 3 MEP reduction and surgery-related paresis. Intraoperative reduction of MEPs in relation to new postoperative impairment in
motor function. Intraoperative MEP amplitude reduction is considered significant when exceeding 50 % (A & B) or 80 % (C & D). Parts
A & C show the data with secondary events. Graphs B & D show cases without secondary events
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of glioma cases. In the BM group 86.0 % (26 patients) were
neurologically unchanged in contrast to 7 % (2 patients)
showing new temporary and 7 % (2 patients) new perman-
ent deficit. One of the 2 patients with a new permanent
paresis developed secondary hemorrhage postoperatively
representing a case of false negative IOM at first glance.
Out of the 24 glioma patients 19 (79.1 %) did not change
postoperatively. Temporary deficit was seen in 4 cases and
one patient developed permanent new deficit due to
secondary ischemia in postoperative MRI, which might
represent another case of false positive IOM. Figure 3c
represents graph including secondary events.
Reversible MEP decline > 80 %
BM cases: In 20 cases (38.0 %) with reversible MEP re-
duction, 80.0 % (16 patients) kept their neurological sta-
tus, 15.0 % (3 patients) showed new transient motor
deficit, and 5 % (1 pt) worsened permanently. Glioma
cases: in 70 (66.7 %) with reversible MEP reduction, the
neurological status was unchanged in 74.3 % (52 patients),
in 18.6 % (13 patients) temporary and in 7.1 % (5 patients)
permanently worsened due to secondary hemorrhage in 4
cases and one case of ischemia.
Irreversible MEP decline >80 %
BM cases: We had 3 cases with irreversible MEP decline
of which 2 cases developed a permanently new paresis and
one case with no new surgery-related motor deficit. Again,
this case has to be considered as a false positive case of
IOM. We have to state that one reasonable explanation
could be the time frame recording only 6.3 – 9.2 min (me-
dian 7.5 min, mean 7.5 min) after 80 % decline. Glioma
cases: These 11 patients with irreversible MEP decline co-
incide exactly with the cases of 50 % MEP decline. Table 3
shows the receiver operating characteristics.
Intraoperative MEP loss
Out of 171 enrolled patients, 3 cases (2 BM and 1 gli-
oma case) had complete intraoperative MEP loss. Both
BM patients showed permanently new paresis. During
surgery we had to stop resection in one patient of the
glioma group due to MEP loss. Nevertheless the exist-
ing preoperative high-grade paresis improved signifi-
cantly after surgery, so this case has to be considered
as a false positive case of IOM. No further explanation
was found even after thorough analyses of anesthesia
protocols.
Postoperative MRI scans
Considering postoperative MRI studies we were able to
detect unexpected residual to the surgeon’s impression
(Fig. 4) and to exclude secondary events for postopera-
tive motor deterioration despite stable MEP amplitudes.
Tumor residual
UR was defined as the difference of the surgeon’s intra-
operative impression of GTR and real GTR on postoper-
ative MRI. In the BM group GTR was expected in
92.5 % and in the glioma-group in 70.6 %. MRI revealed
STR in 28.0 % of all BM cases and in 41.4 % in of all gli-
oma cases. Concerning suspected GTR, MRI revealead an
UR in 21.0 % (BM) and 12.0 % (glioma) of cases (p = 144).
Fig. 4 represents the unexpected residual (UR) in all en-
rolled cases (p = 0.226).
Influence of IOM on the course of surgery
Extent of resection
In 54.7 % of all BM cases and in 65.2 % of all glioma
cases, the neurophysiologist reported significant MEP
deterioration of >50 % of baseline amplitude (Table 1).
In cases of BM with stable MEP residual was found in
27.0 % on postoperative MRI, whereas STR was seen in
37.0 % in glioma cases (p < 0.05). Pausing of surgery due
to MEP reduction or loss was caused in 34.8 % of all
glioma-patients and in 8.0 % of BM patients (p = 0.0002).
Table 3 Receiver Operating Characteristics
Metastases Gliomas
Amplitude decline >50 % >80 % >50 % >80 %
true positive 6.0 % 4.0 % 8.0 % 8.0 %
true negative 70.0 % 89 % 84.0 % 84.0 %
false positive 21.0 % 2.0 % 1.0 % 1.0 %
false negative 4.0 % 6.0 % 6.0 % 6.0 %
negative predictive value 95.0 % 94.0 % 94.0 % 94.0 %
positive predictive value 21.0 % 67.0 % 73.0 % 73.0 %
sensitivity 60.0 % 40.0 % 57.0 % 57.0 %
specificity 77.0 % 98.0 % 97.0 % 97.0 %
Receiver Operating Characteristics (ROC) of MEP monitoring when an amplitude
decline of >50 % or >80 % is considered significant depending on tumor type
Fig. 4 Unexpected residual. Postoperative MRI scan showing
unexpected residual in both groups (p = 0.2265)
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Resection had to be terminated in 15.2 % (17 patients) of
glioma cases and 4.0 % (2 patients) of BM cases (p = 0.037).
The incidence of new permanent motor deficit correlating
with extent of resection was not statistically significant in
both groups (STR: BM cases 25.0 %; glioma cases 11.4 %
and GTR: BM cases 12.2 %; glioma cases 13.0 %).
False positive cases
In the BM group there were those 11 cases (22.0 %) in
which irreversible MEP deterioration occurred during
resection of the metastatic lesion without new surgery-
related permanent deficit. In these cases postoperative
MRI showed suspected residual tumor in 4 patients
(36.4 %). In comparison, only 10 patients with STR out
of the 50 remaining no false positive cases (20 %) were
found (p = 0.0292). Regarding MEP decline >80 % we
only had one false positive case without residual in post-
operative MRI scan. Analysing the glioma data revealed
different results. No matter whether 50 or 80 % MEP de-
cline was used as cutoff, there was only one false positive
case. This patient suffered from preoperative existing
high-grade paresis due to left-sided postcentral GBM.
Intraoperatively MEP loss caused stop of resection and
motor deficit improved postoperatively. Postoperative
MRI showed no residual tumor.
Analysis of IOM characteristics
When analyzing MEP amplitude characteristics post-
hoc, we also examined any amplitude reduction of more
than 25 % as well as any latency prolongation of more
than 10 %. Interestingly, there were differences between
both groups. Regarding mean MEP reduction no statis-
tical difference was found in both groups, whereas the
mean time of reduced MEP only in the glioma group
showed a significant difference between permanent and no
new postoperative deficit (new permanent deficit: 445.1 ±
313.4 s [median 180.1 s; range 60.0 - 1800.0 s]; new tem-
porary deficit: 100.1 ± 141.1 s [median 100.0 s; range 0.0 -
803.7 s]; no new deficit: 88.6 ± 64.3 s [median 80.6 s; range
0.0 - 421.3 s]; p = 0.001). Total MEP decline per recorded
electrode did not reach statistical significance. But again,
only in the glioma group mean time of MEP latency pro-
longation showed a significant difference between postoper-
ative temporary or permanent motor deficit despite severe
standard deviation (new permanent deficit: 142.1 ±
201.4 s [median 113.6 s; range 0.0 - 780.0 s]; new
temporary deficit: 93.0 ± 186.3 s [median 40.0 s; range
0.0 - 816.3 s]; no new deficit: 43.2 ± 67 s [median
0.0 s; range 0.0 - 280.0 s]; p = 0.05).
Discussion
In our study, both groups developed a new permanent
motor deficit (BM 9.4 % vs. 12.5 % glioma), whereas the
number of improved neurological status was much
higher in the BM group (21.0 % vs. 5.4 %). These find-
ings are in accordance to recent studies that reported
similar results of motor function after resection of elo-
quently located lesions [2, 14, 17, 32]. We found a high
number of UR with a trend towards a higher rate of UR
in the BM group (21.0 % vs. 12.0 %; p = 0.144) without
reaching statistical significance. Recently published stud-
ies could show a more infiltrative growth pattern of BM
as expected in the past [1, 7]. The number of cases with
estimated complete resection revealed a significant dif-
ference (p = 0.0013): In 93.0 % of BM cases GTR was ex-
pected by the surgeon in contrast to 72.0 % of GTR on
postoperative MRI, which reflects the underestimation
of real extent of BM.
Correlation of tumor type, location, and postoperative
pareses
In the glioma group we found no significant difference
between WHO grade and surgery-related pareses, but a
trend towards high grade tumors and degree of postop-
erative new paresis was shown, which can be related to a
more aggressive resection of high-grade gliomas. In
terms of tumor location only the BM group showed sta-
tistically significant differences (p = 0.0209), which seems
not plausible at first glance. Regarding our patient co-
hort and its preoperative status (preoperative paresis in
57.0 % of BM vs. 31.3 % in glioma patients), pre-existing
deficit is known to be a risk-factor for postoperatively
aggravated paresis.
Intraoperative neuromonitoring
The MEP evaluated by the neurophysiologist was more
stable in glioma cases (65.2 % vs. 54.7 %). Based on dif-
ferent thresholds of MEP reduction we compared our
results of BM cases with glioma cases in a post-hoc ana-
lysis. Contrary to the postoperative analysis of MEP re-
cordings, the intraoperatively graded findings of the
neurophysiologist show less stable MEP amplitudes during
BM resection (Table 1). However, in the post-hoc analysis,
MEPs were more stable in BM cases no matter what ex-
tent of MEP decline was taken. At a threshold of 80 %
MEP decline we only had one false positive case instead of
11 cases at a MEP decline of 50 % (Table 2). As some other
authors already stated, one reason could be the progressive
depression of MEPs during general anesthesia [33].
As mentioned above, the median time frame of 7.5 min
further recording after MEP decline could be a conceiv-
able reason for missing a supposed MEP recovery. In the
glioma group there was only one false positive case no
matter what MEP decline was chosen to be considered.
The other 10 of 11 cases with irreversible MEP decline all
harbored high-grade gliomas and developed permanent
(n = 8) and temporary (n = 2) pareses.
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False negative cases
In both groups we found patients with suspected false
negative IOM. All these cases could be explained by
secondary events as revealed by postoperative MRI and no
real false negative case was seen. Previous reports on false
negative IOM are rare. Kombos et al. 2001 reported some
false negative cases and Neuloh et al. described 2 patients
with stable MEP recordings and new postoperative tempor-
ary mild facial palsy [32, 34]. Krieg et al. 2012 found no real
false negative case in their study of predictive value of IOM
in glioma surgery and all cases of motor deficits not de-
tected by IOM could be explained by secondary events [2].
The result of no real false negative case of IOM is a very
important information for the surgeon to believe in IOM.
False positive cases
Unfortunately we had to face 11 BM cases and one gli-
oma case that had to be categorized as false positive
cases when using MEP decline >50 % to be considered.
Thus, the positive predictive value (PPV) of both groups
differed considerably (Table 3). When using a MEP de-
cline >80 % as threshold level, the PPV for BM approxi-
mated to the PPV of glioma cases, which shows that
IOM is not the same in both groups and is more reliable
in glioma cases, respectively. Comparing false positive
cases with other BM cases we were most concerned
about the significantly higher rate of STR in false posi-
tive BM cases. One explanation for this high rate of false
positive IOM cases in BM patients could be that BM are
moved within the brain parenchyma during resection
and therefore causing some kind of mass effects in vas-
culature with transient subcortical hypoperfusion while
gliomas are resected without moving the tumor and
therefore causing less pressure on surrounding brain tis-
sue. Another explanation may be the high rate of already
existing preoperative pareses in BM patients. However,
we have to keep in mind that only half of these 11 pa-
tients suffered from preoperative pareses. Worth men-
tioning that no matter which threshold was used for
MEP decline, there was no difference of PPV for glioma
patients. Yet, we could not find any reason for the one
false positive glioma case in this retrospective setup.
Influence of IOM on the course of surgery
Pausing of resection due to MEP reduction or loss occurred
significantly more frequently in glioma cases (p = 0.0002).
The same result was found in cases where resection had to
be stopped due to MEP decline (p = 0.0375) (Fig. 5). A
trend of more STR in glioma cases was also seen which can
be explained by the more infiltrative growth of pattern
compared to BM. One can say that this indicates a negative
influence of IOM on the extent of resection. However,
Kombos et al. reported 2009 no negative impact of IOM on
surgery of high-grade gliomas [14]. Other studies already
showed a benefit of IOM during eloquently located lesions
[32] and these findings seem to be reasonable since IOM
may limit resection to prevent functional damage and to
save quality of life which is the same intention of treatment
in both groups.
Analysis of IOM characteristics
We had to face a low rate of stable MEPs in both groups
with a trend to more stable MEP recordings in gliomas
as graded by the neurophysiologist. Yet, small changes
of MEPs did not correlate with development of postop-
erative new paresis, which was stated by several studies
previously [2, 16, 30, 34]. Furthermore a problem was
the high rate of presumably false positive IOM cases of
BM, if a threshold for MEP-decline >50 % was used. This
indicates that different thresholds of MEP reduction have
to be adapted to the patient’s lesion [14, 32, 34]. No matter
what kind of lesion we were dealing with, IOM should be
combined by diffusion tensor imaging fiber tracking, sub-
cortical stimulation and navigated transcranial magnetic
stimulation (nTMS). Furthermore monitoring of somato-
sensory evoked potentials can help us to estimate proxim-
ity of the CST, detect changes despite stable MEPs and
increase the safety of resection [16, 27, 35, 36].
Potential changes and postoperative outcome
IOM-related complications were very rare in this series,
again pointing to the safety of IOM itself and the algo-
rithms used in this considerably large series. All pre-
sumed false negative results in IOM can be explained by
secondary hemorrhage or ischemia (Table 2). As some
previous studies reported, if postoperative MRI scan
showed no pathology, new postoperative motor deficit
was always transient [2, 3]. We have to keep in mind that
the shorter duration of follow-up in BM cases (0.7 months
vs 6.1. months in glioma cases) maybe could not detect a
Fig. 5 Stop of resection. Stop of resection due to decline in muscular
evoked potential (MEP) amplitude below 50 % baseline in metastases
and gliomas (p = 0.0375)
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recovery from permanent deficit. Apart from motor func-
tion, we still have to face the problem that we are unable
to detect visual impairment or distinctive neuropsycho-
logical changes by only using cortical MEPs. Concerning
the observed differences between IOM in metastases and
gliomas the physiological or technical reasons are still not
clear. Yet, this important issue has to undergo further in-
vestigation by a broad neurophysiological community.
Limitations
In none of our cases intraoperative electrocorticography
was used to detect intraoperative seizures as a confound-
ing factor of the acquired IOM data. Senft et al. used
multimodality such as intraoperative MRI combined
with IOM to extend resection [37].
In BM cases stimulation of up to 20 mA and in one
glioma case an intensity up to 30 mA was applied and
therefore especially subcortical axons could be activated.
In all these cases MEPs were stable and the patients de-
veloped no deterioration postoperatively. Routinely we
used stimulation intensity of 6–12 mA.
We are aware of the fact that our median follow-up in
BM group (0.7 months) does not allow defining a per-
manent deficit.
Most importantly, we also have to mention that the
retrospective review of the patients’ outcome data might
also have affected the results. Yet, due to the standardized
neurological evaluation and follow-up of our patients, the
loss of clinical information seems rather small. The short
time of ongoing IOM after MEP decline or loss has to be
considered, as maybe the rate of irreversible decline of
MEP would have been lower.
Another major limitation of this study is that both
groups differ in the number of lesions per patient, tumor
location, follow-up, age, and baseline motor status
(Table 1). However, due to the generally followed guide-
lines for indication of metastases resection, there is no
option to provide two homogeneous groups to compare.
Nonetheless, the differing baseline motor status might
indeed be the reason for a significantly higher number
of improved pareses in the BM group.
Conclusion
By analyzing the results of MEP monitoring, we found a
difference between glioma and metastases resection.
MEPs in BM patients were more stable than in glioma
patients in the post-hoc analysis. Moreover, the thresh-
old for considerable MEP decline has to be chosen dif-
ferently in glioma and BM surgery to reach the same
level of reliability. Due to a surprisingly high rate of
surgery-related new paresis in BM patients and therefore
a remarkably higher rate of false negative IOM, an amp-
litude decline >80 % can be recommended for BM
surgery, whereas this issue does no make any difference
in glioma cases.
Right now, we do not know the reason for the ob-
served differences. Thus, this report should motivate the
IOM community to clarify this issue in order to provide
improved care for our patients.
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